Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 38.7% in June

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 16,698 shares, a decrease of 38.7% from the June 15th total of 27,250 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average trading volume of 39,560 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

BOLT has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. Finally, Rodman & Renshaw started coverage on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $34.67.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in Bolt Biotherapeutics by 40.3% in the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after acquiring an additional 22,200 shares in the last quarter. T3 Companies LLC purchased a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $208,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth $112,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the 3rd quarter worth $89,000. Finally, Shay Capital LLC purchased a new position in Bolt Biotherapeutics during the 3rd quarter worth $85,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Up 5.5%

Bolt Biotherapeutics stock traded up $0.23 during midday trading on Friday, hitting $4.42. 15,969 shares of the company’s stock were exchanged, compared to its average volume of 19,670. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The company has a market cap of $8.49 million, a PE ratio of -0.27 and a beta of 1.16. The firm has a 50-day moving average of $4.47 and a two-hundred day moving average of $4.88. Bolt Biotherapeutics has a 12 month low of $3.75 and a 12 month high of $7.20.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%. As a group, analysts expect that Bolt Biotherapeutics will post -11.1 earnings per share for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.